TGen (Translational Genomics Research Institute). According to its website, TGen:
- "employs innovative advances arising from the Human Genome Project by applying them to the development of diagnostics, prognostics, and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine and the institute plans to accomplish its goals through robust and disease-focused research."
The TGen Foundation raises funds for TGen.
Income for TGen has nearly tripled revenue over the past five fiscal years. The money comes from grants, contracts, donations and other sources. The Arizona Republic reported the income for TGen as being:
- 2007: $51.7 million.
- 2006: $48.9 million.
- 2005: $34 million.
- 2004: $21 million.
- 2003: $18.3 million.
The Arizone Republic reported the time line for the development of TGen as being:
- February 2002: Arizona leaders seek to foster growth of the biosciences in Arizona and pledge $100 million for a genomic research institute.
- June 2002: Dr. Jeff Trent agrees to come to Arizona to lead TGen.
- December 2002: TGen forms its board of directors.
- August 2002 - January 2003: TGen operates from four temporary locations.
- December 2004: TGen moves into a new research lab in downtown Phoenix and later establishes satellite facilities in Flagstaff and Scottsdale.
- 2004-2007: TGen adds more than 100 employees and pursues research in three disease areas: cancer, diabetes and neurology. It forges ties with other Arizona clinical research groups.
- October 2007: Along with ASU's Biodesign Institute, TGen secures $45 million in pledges from Flinn Foundation and Virginia G. Piper Charitable Trust to launch a personalized-medicine initiative. It recruits Nobel Prize winner Lee Hartwell to head the effort.
- Micheal Berens, PhD, Director, Cancer and Cell Biology Division; Head, Brain Tumor Research Lab. 
445 N. Fifth Street
Phoenix, AZ 85004
Main Number 602.343.8400